Business Wire

First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Heart Pump Designed for Surgeons

Share

Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Administration (FDA) granted Impella 5.5 with SmartAssist its highest level of approval for safety and efficacy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201105005280/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Impella 5.5 with SmartAssist heart pump helped Keith Brown, 64, recover from a heart attack. (Photo: Business Wire)

In October 2019, the first U.S. patients were successfully treated by cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center. Since then, more than 120 hospitals in the U.S. and Europe have implanted the temporary heart pump.

The first 1,000 patients were treated primarily for cardiomyopathy, AMI cardiogenic shock, and post-cardiotomy cardiogenic shock, with an average duration of support of 14 days. (see figure 1) Uses of Impella 5.5 with SmartAssist include:

  • Escalating a patient’s care to a higher level of cardiac support
  • Providing bi-ventricular support, when used in combination with Impella RP
  • Unloading the left ventricle of patients on ECMO, a combination therapy known as ECpella

In July, a study published in the American Society for Artificial Internal Organs (ASAIO) Journal found 84% survival to explant for Impella 5.5 with SmartAssist patients in cardiogenic shock and other challenging cardiac conditions. 76% of those patients achieved native heart recovery.

In August, the FDA granted Impella 5.5 with SmartAssist, and other left-side Impella heart pumps, an emergency use authorization (EUA) to treat certain patients with COVID-19 related complications who are undergoing ECMO treatment.

In October, the 2020 expert consensus from EACTS, ELSO, STS and AATS named Impella as a Class IIb recommendation as the primary or concomitant treatment option for post-cardiotomy cardiogenic shock with severe isolated left ventricular dysfunction. Impella is now recommended in 10 society clinical guidelines and consensus statements.

“We, as heart failure cardiologists and cardiac surgeons, are understanding the effectiveness of Impella 5.5 with SmartAssist as an unprecedented new option for cardiogenic shock patients as a bridge to recovery or bridge to next therapy,” said Shelley Hall, MD, chief, transplant cardiology, MCS and heart failure at Baylor Scott and White Dallas. “This fully unloading device allows us to treat hemodynamically challenged patients faster and easier with improved outcomes. The Impella 5.5 with SmartAssist is contributing to saving lives and giving these critically ill patients a chance at survival.”

One such patient is 64-year-old Keith Brown. After Keith collapsed and went into cardiac arrest, initial treatment methods weren’t effective. That’s when Michael Kwan, MD, and Masahiro Ono, MD, from Methodist Hospital in San Antonio, escalated Keith’s care and implanted Impella 5.5 with SmartAssist to provide maximum support and optimize the opportunity for Keith’s heart to recover.

Keith’s condition immediately began to improve, and he was able to walk around the hospital while on Impella support. The SmartAssist technology helped the physicians with patient management and assisted in weaning Keith off Impella after four days on support. Keith fully recovered and went home with his native heart. Today, Keith cares for his elderly father, enjoys time with his two children, and looks forward to traveling more with his wife.

“The Impella 5.5 with SmartAssist is a promising option for heart failure patients in cardiogenic shock,” said Mani Daneshmand, MD, director of heart & lung transplantation and mechanical circulatory support at Emory University Hospital. “A forward flow, minimally invasive heart pump gives surgeons an important new tool. With this heart pump, we have seen exceptional outcomes for our patients.”

“This heart pump is markedly improving the standard of care and enabling the management of higher risk cardiac surgery patients with a reduced left ventricular ejection fraction. It is incredible to have the opportunity to bring this advanced technology to our patients and see the improved outcomes firsthand,” said Raymond Lee, MD, a cardiothoracic surgeon at Providence Health in Santa Monica, California.

Impella 5.5 with SmartAssist delivers peak flows of greater than 6 liters per minute. Benefits of the Impella 5.5 with SmartAssist include:

  • Impella Connect, providing cloud-based remote monitoring in the COVID-19 era
  • Ease of insertion, via the axillary artery or anterior aorta
  • Designed for long-duration support, with patient ambulation, ceramic bearings and no pigtail
  • Forward flow with maximum unloading, to provide end organ and coronary perfusion and allow the heart to rest
  • Enables heart recovery, as a minimally invasive, weanable VAD
  • Ease of patient management, can be intelligently positioned, weaned and managed with SmartAssist

It is available in the U.S. and Europe for hospitals with established heart recovery protocols.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

ABOUT IMPELLA HEART PUMPS

The Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Impella Left Ventricular (LV) Support Systems are also authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0 and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac decompensation from myocarditis while on V-V ECMO support. The authorized Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella RP and Impella LV Support Systems have been authorized for the above emergency use by FDA under an EUA and have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

The Impella RP® is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.

The Impella RP is also authorized for emergency use by healthcare providers (HCPs) in the hospital setting for providing temporary right ventricular support for up to 14 days in critical care patients with a body surface area ≥1.5 m2, for the treatment of acute right heart failure or decompensation caused by complications related to coronavirus disease 2019 (COVID-19), including pulmonary embolism (PE). The Impella RP has not been cleared or approved for the treatment of acute right heart failure or decompensation caused by complications related to COVID-19.

Impella Left Ventricular (LV) Support Systems are also authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0 and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac decompensation from myocarditis while on V-V ECMO support. The authorized Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella RP and Impella LV Support Systems have been authorized for the above emergency use by FDA under an EUA and have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

FORWARD-LOOKING STATEMENTS

Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sarah Karr
Communications Manager
(978) 882-8211
skarr@abiomed.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Northleaf Appoints Shane Feeney to Lead and Expand Its Well-established Global Secondaries Business22.6.2021 21:00:00 EEST | Press release

Northleaf Capital Partners (Northleaf) today announced that Shane Feeney has joined the firm as Global Head of Secondaries, based in Toronto. In this role, Feeney will oversee all aspects of Northleaf’s secondaries program, building on the firm’s highly successful 18-year track record in global secondary investing and enhancing existing team capabilities as the secondaries market continues to expand rapidly. Feeney most recently served as Senior Managing Director & Global Head of Private Equity at CPP Investments, one of the world’s largest institutional investors with $497.2 billion in assets under management as of March 31, 2021. In this role, Feeney led the teams responsible for CPP Investments’ direct private equity, Asia private equity, private equity funds and secondaries investments. Under Feeney’s leadership, CPP Investments’ private equity program assets under management grew by approximately $73.6 billion. In fiscal 2021, CPP Investments’ private equity program generated a ne

SES Successfully Prices EUR 150 Million Tap of 2026 Eurobond22.6.2021 19:46:00 EEST | Press release

SES S.A. announced today the successful launch and pricing of a tap of its 1.625% Notes due 22 March 2026 in which it has agreed to sell incremental senior unsecured fixed rate notes for a total amount of EUR 150 million. The new notes were priced at 106.665% of their nominal value representing a credit spread of 47bps and a yield-to-maturity of 0.207%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005953/en/ SES Successfully Prices EUR 150 Million Tap of 2026 Eurobond (Photo: Business Wire) SES is rated Baa2 by Moody’s (with negative outlook) and BBB- by Standard & Poor’s (with stable outlook). Proceeds of the issuance will be used for general corporate purposes. BBVA, Deutsche Bank and IMI Intesa Sanpaolo acted as Joint Bookrunners. The settlement is scheduled for 29 June 2021 and application has been made for the notes to be listed on the Luxembourg Stock Exchange. The securities were placed with a broad range of i

Safic-Alcan Extends Its Distribution Agreement With PMC Organometallix to the African Continent22.6.2021 19:35:00 EEST | Press release

Safic-Alcan, a global specialty chemicals distributor, is pleased to announce the extension of its distribution agreement with PMC Organometallix Inc. to the African continent. PMC Organometallix, Inc., a wholly owned subsidiary of PMC Group, N.A., Inc. has expanded its distribution agreement with Safic-Alcan to include the African continent. Effective immediately, Safic-Alcan will serve as an authorized distributor of PMC Organometallix’s FASCAT® catalysts and fine chemicals. FASCAT® catalysts are inorganic and organometallic tin compounds providing optimal conversion and curing characteristics - making these organometallic materials essential in a wide variety of applications. FASCAT® catalysts are used in the manufacture of synthetic lubricants, monomeric and polymeric ester synthesis, automotive e-coat, crosslinking of siloxanes, urethanes and chemical intermediates. “Building on our successful partnership with Safic-Alcan in continental Europe, we are pleased to extend our collabo

In Celebration of World Rainforest Day, 33 Qualified Teams and 9 Judges Announced in $10M XPRIZE Competition to Improve Understandings and Preservation of the Planet’s Rainforests22.6.2021 19:24:00 EEST | Press release

XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially announced today the teams moving forward in the $10M XPRIZE Rainforest aimed at improving our understanding of the rainforest ecosystem. Sponsored by Alana Foundation, the five-year XPRIZE Rainforest is a call-to-action to help save rainforests through the development of transformative, scalable, and affordable technology to autonomously survey and monitor biodiversity in real-time, leading to insights that communicate the health, well-being, and value of standing tropical rainforests. XPRIZE Rainforest is co-developing an inclusive framework throughout all stages of the competition that ensures competing teams co-design and co-create solutions with Indigenous Peoples and local communities as key stakeholders and not just beneficiaries. These 33 teams will now leverage existing and emerging technologies, such as robotics, remote sensing, data analysis, artificial

BourseInside, The New Media Platform That Finds Attractive Investments for Curious Investors22.6.2021 18:08:00 EEST | Press release

On the stock market, small caps continue to outperform. Since 1926, they have posted a performance of 12.1% per year, in contrast to 9.7% for large caps. And yet these so-called "small stocks" have been largely ignored by the stock market. They are rarely covered by analysts, shunned by the mainstream stock-market press and neglected by funds. Nevertheless, they are of great interest to investors, in particular those who have recently taken to investing in the stock market in order to grow their savings (16% increase in investors in 2020). For half of these newcomers, investing in the stock market gives them the opportunity to support the French economy by supporting the growth of our future champions and to channel their savings into a more sustainable and fairer model. In order to further strengthen this link between the French people and the development of our national companies, we decided to create BourseInside, the first web/TV/newsletter media platform, fully dedicated to listed

DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma22.6.2021 17:31:00 EEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation in two new indications. The first authorisation of these new indications is for the use of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis. This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe. The second authorisation is for the use of daratumumab SC in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of adults with multiple myeloma (MM) who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor, and have

PPG Introduces Digital Color-Matching Device for Commercial Vehicles22.6.2021 16:02:00 EEST | Press release

PPG (NYSE: PPG) today announced the introduction of its ColorReader portable digital device, which will enable customers in the commercial vehicle sector to quickly and precisely match colors to the PPG DELFLEET ONE® color palette and international standard colors. ColorReader is a BLUETOOTH®-connected device that works with a dedicated app. Available for iOS and Android tablets and smartphones, the device provides a highly accurate color match in just a few seconds. “All users have to do is download the ColorReader app, connect with their smartphone or tablet, and place ColorReader on the painted surface to scan,” said Jo Thompson, PPG color marketing manager, automotive refinish, Europe, Middle East and Africa. “ColorReader also offers a smart solution when a smartphone or tablet is not available by instantly displaying the three closest matching colors on its built-in display after scanning.” PPG recently launched ColorReader in Europe, the Middle East and Africa, and has received a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom